<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02545738</url>
  </required_header>
  <id_info>
    <org_study_id>2014-004502-15</org_study_id>
    <nct_id>NCT02545738</nct_id>
  </id_info>
  <brief_title>Antiproteinuric Effects of Liraglutide Treatment</brief_title>
  <acronym>LIRALBU</acronym>
  <official_title>Antiproteinuric Effects of Liraglutide Treatment in Patients With Type 2 Diabetes and Albuminuria: A Randomised, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steno Diabetes Center Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Steno Diabetes Center Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the effect of Liraglutide on albuminuria in type 2&#xD;
      diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Initial findings point to a clinically significant antiproteinuric effect of liraglutide&#xD;
      treatment, possibly independent from blood pressure reduction. The mechanism behind is&#xD;
      unclear and the magnitude of albuminuria reduction needs to be verified. Antiproteinuric&#xD;
      effects are usually renoprotective and potentially also cardioprotective and may suggest an&#xD;
      additional benefit from liraglutide treatment.&#xD;
&#xD;
      The aim of this study is to evaluate the magnitude of the antiproteinuric effect of&#xD;
      short-term liraglutide treatment (12 weeks) in patients with type 2 diabetes and albuminuria.&#xD;
      In addition, possible mechanisms causing the antiproteinuric effect will be explored.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in albuminuria</measure>
    <time_frame>24 weeks</time_frame>
    <description>24h urinary albumin excretion rate (UAER mg/24h)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in renin-angiotensin system hormones</measure>
    <time_frame>24 weeks</time_frame>
    <description>renin (activity and concentration), angiotensin 1+2, aldosteron (concentrations)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in kidney function</measure>
    <time_frame>24 weeks</time_frame>
    <description>Cr-EDTA-GFR (ml/min/1.73m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24h blood pressure</measure>
    <time_frame>24 weeks</time_frame>
    <description>24 h systolic and diastolic blood presure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in markers of inflammation</measure>
    <time_frame>24 weeks</time_frame>
    <description>TNF-alfa, mcp (concentration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24h heart rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>puls in BPM</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Diabetic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liraglutide s.c. up-escalated to 1.8 mg/day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo s.c. for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>active treatment</description>
    <arm_group_label>Liraglutide</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must give written informed consent before participation. Patient information and&#xD;
             consent form must be approved by the Danish Medicines Agency and the Regional&#xD;
             Scientific Ethical Committee&#xD;
&#xD;
          2. Male or female patients &gt;18 years with type 2 diabetes (WHO criteria).&#xD;
&#xD;
          3. HbA1c ≥ 48 mmol/mol (6.5 %)&#xD;
&#xD;
          4. eGFR ≥ 30 ml/min/1.73 m2 (estimated by MDRD formula)&#xD;
&#xD;
          5. Fertile female patients must use chemical, hormonal or mechanical contraceptives or be&#xD;
             in menopause (i.e. must not have had regular menstrual bleeding for at least one year)&#xD;
             or have undergone bilateral oophorectomi or have been surgically sterilized or&#xD;
             hysterectomised at least six months prior to screening&#xD;
&#xD;
          6. Patients must be on stable RAAS-blocking treatment (unchanged dose 4 weeks before&#xD;
             inclusion)&#xD;
&#xD;
          7. Geometic mean urine albumin-to-creatinine ratio (UACR) above 30 mg/g at screening&#xD;
             (measured in at least two of three consecutive morning spot urine samples)&#xD;
&#xD;
          8. Systolic blood pressure (SBP) must be lower than 180 mm Hg at screening.&#xD;
&#xD;
          9. Patients must be on stable glucose lowering medication for at least two weeks before&#xD;
             the first visit.&#xD;
&#xD;
         10. Must be able to communicate with the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. SBP &gt; 180 mm Hg at screening&#xD;
&#xD;
          2. Type 1 diabetes mellitus&#xD;
&#xD;
          3. Chronic pancreatitis / previous acute pancreatitis&#xD;
&#xD;
          4. Known or suspected hypersensitivity to trial product(s) or related products.&#xD;
&#xD;
          5. Treatment with oral glucocorticoids, calcineurin inhibitors, dipeptidyl peptidase 4&#xD;
             (DPP4) inhibitors, glucagon like peptide-1 agonists and sodium-glucose co-transporter&#xD;
             2 (SGLT-2) inhibitors, which in the investigator's opinion could interfere with&#xD;
             glucose or lipid metabolism 90 days prior to screening&#xD;
&#xD;
          6. Cancer (except basal cell skin cancer or squamous cell skin cancer) or any other&#xD;
             clinically significant disorder, except for conditions associated with type 2 diabetes&#xD;
             history, which in the investigators opinion could interfere with the results of the&#xD;
             trial&#xD;
&#xD;
          7. Inflammatory bowel disease&#xD;
&#xD;
          8. Cardiac disease defined as: Decompensated heart failure (NYHA class III-IV) and/or&#xD;
             diagnosis of unstable angina pectoris and/or myocardial infarction within the last 6&#xD;
             months&#xD;
&#xD;
          9. Previous bowel resection&#xD;
&#xD;
         10. Body mass index &lt;18.5 kg/m2&#xD;
&#xD;
         11. Females of childbearing potential who are pregnant, breast-feeding, intending to&#xD;
             become pregnant or not using adequate contraceptive methods&#xD;
&#xD;
         12. Clinical signs of diabetic gastroparesis&#xD;
&#xD;
         13. Impaired liver function (transaminases &gt; two times upper reference levels)&#xD;
&#xD;
         14. The receipt of any investigational product 90 days prior to this trial&#xD;
&#xD;
         15. Known or suspected abuse of alcohol or narcotics&#xD;
&#xD;
         16. Subjects with personal or family history of medullary thyroid carcinoma or a personal&#xD;
             history of multiple endocrine neoplasia type 2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Rossing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steno Diabetes Center Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peter Rossing</name>
      <address>
        <city>Gentofte</city>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>April 13, 2015</study_first_submitted>
  <study_first_submitted_qc>September 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2015</study_first_posted>
  <last_update_submitted>August 9, 2016</last_update_submitted>
  <last_update_submitted_qc>August 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Steno Diabetes Center Copenhagen</investigator_affiliation>
    <investigator_full_name>Peter Rossing</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

